糖尿病损害代偿期肝硬化患者对非选择性β受体阻滞剂的血流动力学应答并易致肝功能失代偿
本研究回顾性纳入92例接受配对肝静脉压力梯度(HVPG)测量的代偿期晚期慢性肝病(cACLD)患者,评估代谢合并症对非选择性β受体阻滞剂(NSBB)血流动力学效应及肝功能失代偿的影响。结果显示糖尿病(OR: 0.35, p=0.021)和较高BMI(每kg/m2 OR: 0.89, p=0.031)降低HVPG应答率;糖尿病(aSHR: 2.8, 95%CI:1.1-7.2, p=0.036)独立增加肝功能失代偿风险。
要点
- 糖尿病(OR: 0.35, p=0.021)和较高BMI(每kg/m2 OR: 0.89, p=0.031)与HVPG应答率降低相关。
- 糖尿病(aSHR: 2.8, 95%CI:1.1-7.2, p=0.036)独立增加肝功能失代偿风险。
- Child-B(aSHR: 4.3, 95%CI:1.5-12.2, p=0.006)和HVPG应答(aSHR: 0.3, 95%CI:0.1-0.9, p=0.037)与肝功能失代偿独立相关。
核心结论
- 在cACLD患者中,糖尿病和较高BMI损害HVPG对NSBB的应答。
- 糖尿病独立于Child-B分级和HVPG应答缺失,增加肝功能失代偿风险。
研究设计与样本
- 回顾性研究,纳入92例接受NSBB治疗前后配对HVPG测量的cACLD患者(Child-A n=80, 87%;Child-B n=12, 13%)。
- 记录代谢合并症(肥胖、血脂异常、糖尿病)基线特征及随访期间肝功能失代偿和肝相关死亡。
主要发现
- 代谢合并症见于34例(37%)患者:肥胖19例(20.7%)、血脂异常14例(15.2%)、糖尿病23例(34.8%)。
- 基线HVPG中位数18(IQR:15-21)mmHg降至NSBB治疗下15(IQR:9-12)mmHg,HVPG应答(下降≥10%或至≤12 mmHg)60例(65.2%)。
- 中位随访2.3(0.5-4.2)年,18例(19.5%)发生肝功能失代偿。
- 糖尿病(OR: 0.35, p=0.021)和较高BMI(每kg/m2 OR: 0.89, p=0.031)与HVPG应答率降低相关。
- 肝功能失代偿独立相关因素:Child-B(aSHR: 4.3, 95%CI:1.5-12.2, p=0.006)、HVPG应答(aSHR: 0.3, 95%CI:0.1-0.9, p=0.037)、糖尿病(aSHR: 2.8, 95%CI:1.1-7.2, p=0.036)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-selective betablockers (NSBBs) reduce the risk of hepatic decompensation in patients with compensated advanced chronic liver disease (cACLD). Metabolic co-morbidities (MetC) are increasingly observed in cACLD patients. AIMS: To investigate the impact of MetC on the haemodynamic effects of NSBB and hepatic decompensation in cACLD. METHODS: cACLD patients undergoing paired hepatic venous pressure gradient (HVPG) measurements before/under NSBB therapy were retrospectively considered for this study. We recorded baseline characteristics on MetC (obesity, dyslipidaemia and diabetes), as well as hepatic decompensation and liver-related mortality during follow-up. RESULTS: We included 92 patients (Child-A n = 80, 87%; Child-B n = 12, 13%). MetC were found in 34 (37%) patients: 19 (20.7%) with obesity, 14 (15.2%) with dyslipidaemia and 23 (34.8%) with diabetes. The median baseline HVPG of 18 (IQR:15-21) mmHg decreased to 15 (IQR:9-12) mmHg under NSBB. HVPG-response (decrease ≥10% or to ≤12 mmHg) was achieved in 60 (65.2.%) patients. Patients with diabetes (OR: 0.35, p = 0.021) and higher BMI (OR: 0.89 per kg/m2 , p = 0.031) were less likely to achieve HVPG-response. During a median follow-up of 2.3 (0.5-4.2) years, 18 (19.5%) patients experienced hepatic decompensation. Child-B (adjusted subdistribution hazard ratio, aSHR: 4.3 [95% CI:1.5-12.2], p = 0.006), HVPG-response (aSHR: 0.3 [95% CI:0.1-0.9], p = 0.037) and diabetes (aSHR: 2.8 [95% CI:1.1-7.2], p = 0.036) were independently associated with hepatic decompensation. CONCLUSIONS: In patients with cACLD, diabetes and a higher BMI impair the HVPG-response to NSBB. Furthermore, diabetes-independently from Child B and lack of HVPG-response-increases the risk of hepatic decompensation.
引用
- Paternostro R, Jachs M, Hartl L, et al. Diabetes impairs the haemodynamic response to non-selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023. PMID: 37519146. doi:10.1111/apt.17653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。